DEVELOPMENT OF TECHNOLOGY OF OBTAINING OF MICROBIAL HYALURONIDASE AND MEDICINES ON ITS BASIS

Issue: 
1
Year: 
2016

R.U. Khabriev
Dr.Sc. (Med.), Dr.Sc. (Pharm.), Professor, Academician of the Russian Academy of Sciences,
Director of «National Institute of public health named after N.A. Semashko» (Moscow)
E-mail: institute@nriph.ru
N.O. Kamaev
Ph.D. (Pharm.), Executive Director of the Association «The Russian Anti-Doping Agency RUSADA» (Moscow)
E-mail: rusada@rusada.ru
T.I. Danilova
Ph.D. (Biol.), Senior Research Scientist, Consultant-Technologist, Ltd. «Biocenter» (Moscow)
E-mail: t.i.danilova@mail.ru
E.G. Kakhoyan
General Director of the Russian pharmaceutical company «Pharma» (Moscow)
E-mail: ekakhoyan@yahoo.ru

The article describes the conditions of optimization of technology of production of biotechnology hyaluronidase of Streptomyces actinocidus 77 in order to maximize the preservation of native structure and maintaining the molecules of the enzyme in a functionally active form at all stages of the process. The result of this research is the formulation of the drug based on this enzyme.

Keywords: 
Key words: biotechnology hyaluronidase
purification on carboxylic cation exchanger
the discoloration of the eluates
ultrafiltration
excipient (stabilizer) – mannitol.